한글목차

세계 호흡기세포융합바이러스(RSV) 치료 시장의 미래는 팔리비주맙과 리바비린 시장에 기회가 있으며, 유망한 것으로 전망되고 있습니다. 세계 호흡기세포융합바이러스(RSV) 치료제 시장은 2025-2031년 13.2%의 연평균 복합 성장률(CAGR)로 2031년까지 약 34억 달러에 달할 것으로 예측됩니다. 이 시장의 주요 촉진요인은 호흡기세포융합바이러스 감염 빈도 증가와 이환율 증가입니다.

• Lucintel의 예측에 따르면, 치료별로는 면역 예방약이 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.
• 약제별로는 팔리비주맙이 가장 높은 성장이 예상됩니다.
• 지역별로는 북미가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.

호흡기세포융합바이러스(RSV) 치료제 시장에서의 전략적 성장 기회

시장은 RSV 치료 도구의 부활에 의해 지배되고 있지만, 몇 가지 분야에서 전략적 성장 기회가 있습니다.

• 백신 추가 개발: 백신 연구 및 개발의 가능성은 RSV 감염을 예방하기 위해 유아를 포함한 모든 인구 집단에 매우 중요합니다. 효과적인 예방접종은 상업적으로 실행 가능한 선택이며, 질병 부담과 관련 치료 비용을 줄이는 데 도움이 될 수 있습니다.
• 새로운 항바이러스제 혁신적인 항바이러스제에 초점을 맞추면 RSV 카테고리에서 기존 치료법의 격차를 메울 수 있습니다. 효율적인 항바이러스제의 도입은 특히 중증 RSV 환자의 회복을 촉진하여 많은 사람들에게 혜택을 줄 수 있습니다.
• 소아 의료 분야의 성장: RSV 치료에 대한 관심이 높아짐에 따라 영유아 전문센터 및 관리 계획 등 소아 의료 시설을 개선할 수 있는 기회가 있습니다.
• 진단의 발전: 최신 진단 도구의 도입으로 환자의 RSV 조기 발견이 용이해져 조기 치료와 치료 성적이 향상될 것으로 기대할 수 있습니다.
• 교육 및 인식 제고 프로그램: 간병인과 의료진이 RSV를 쉽게 식별하고 관리할 수 있도록 타겟팅된 메시지와 인식 제고 캠페인을 개발하여 RSV를 조기에 발견하고 관리할 수 있도록 돕고, 조기 관리와 입원을 용이하게 합니다.

이러한 성장 기회는 호흡기세포융합바이러스(RSV) 치료 시장을 개선하고, 예방 및 치료 대책을 강화하며, 궁극적으로 환자 예후를 개선하는 데 중요한 역할을 합니다.

호흡기세포융합바이러스(RSV) 치료제 시장 활성화 요인 및 과제

RSV 치료제는 개발 및 성장을 가속하거나 도전이 되는 많은 요인에 직면해 있기 때문에 매우 복잡합니다.

호흡기세포융합바이러스(RSV) 치료제 시장을 이끄는 요인은 다음과 같습니다.

• RSV에 대한 보건의료 전문가뿐만 아니라 사회적으로도 호흡기세포융합바이러스와 그 고위험군에 미치는 영향에 대한 관심이 높아지고 있습니다. 이에 따라 효과적인 치료법과 예방법에 대한 수요가 증가하고 있습니다.
• 의학연구의 발전: 의학연구의 발전은 항상 무위도식이며, 단클론 항체나 백신 등 RSV 관리를 위한 치료 옵션이 늘어날 것으로 예상됩니다.
• 정부 지원 및 자금 지원: RSV 질환에 초점을 맞춘 프로그램과 적절한 치료 및 백신 개발을 촉진하는 효과적인 공중보건 접근법에 대한 정부의 지원과 자금 지원이 크게 증가하고 있습니다.
• RSV 발생률 증가: 특히 영유아 및 노인의 RSV 발생률이 높아짐에 따라 건강 위험에 대한 효과적인 치료 및 예방법 개발이 시급한 실정입니다.
• 헬스케어 분야의 세계 협력: 의료진, 산업계, 기타 이해관계자간의 혁신적이고 협력적인 접근방식으로 RSV 질환에 대한 다양한 전략 개발이 가속화되고 있습니다.

호흡기세포융합바이러스(RSV) 치료제 시장의 과제는 다음과 같습니다.

• 규제 장애물: 새로운 치료법이나 백신의 승인에 필요한 임상 증거를 수집하고 관료적인 규제 절차를 통과하는 것은 개발자에게 큰 도전이며, 시장 진입 시점에 영향을 미칠 수 있습니다.
• 연구개발비용: RSV 치료제 연구개발에 많은 비용이 소요되기 때문에 특히 중소기업의 경우 막대한 비용이 소요되어 혁신적인 치료제 시장 진입이 제한될 수 있습니다.
• 일반 대중의 인식과 인식: RSV에 대한 인식이 개선되고 있지만, 예방 및 치료 전략에 영향을 미치는 오해가 여전히 존재합니다. 효과적인 교육 노력이 계속 필요합니다.

효과적인 시장 성장 촉진요인과 제약 요인은 RSV 치료제 시장에서 중요한 역할을 하며 신약 개발에 영향을 미칩니다. 이러한 과제를 해결하는 것은 환자의 건강을 개선하고 RSV 관리를 새로운 차원으로 끌어올리고자 하는 모든 이해관계자들의 주요 목표입니다.

목차

제1장 주요 요약

제2장 세계의 호흡기세포융합바이러스(RSV) 치료제 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 호흡기세포융합바이러스(RSV) 치료 시장 동향(2019년-2024년)과 예측(2025년-2031년)
• 약제별 : 세계의 호흡기세포융합바이러스(RSV) 치료 시장
  • Palivizumab
  • Ribavirin
  • 기타
• 치료별 : 세계의 호흡기세포융합바이러스(RSV) 치료 시장
  • 면역 예방
  • 지지 요법
  • 항바이러스제
• 투여 형태별 : 세계의 호흡기세포융합바이러스(RSV) 치료제 시장
  • 경구
  • 주사 가능
  • 기타
• 환자 유형별 : 세계의 호흡기세포융합바이러스(RSV) 치료 시장
  • 소아
  • 성인

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 지역별 : 세계의 호흡기세포융합바이러스(RSV) 치료 시장
• 북미의 호흡기세포융합바이러스(RSV) 치료 시장
• 유럽의 호흡기세포융합바이러스(RSV) 치료제 시장
• 아시아태평양의 호흡기세포융합바이러스(RSV) 치료 시장
• 기타 지역의 호흡기세포융합바이러스(RSV) 치료 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 치료제별 : 세계의 호흡기세포융합바이러스(RSV) 치료 시장 성장 기회
  • 치료별 : 세계의 호흡기세포융합바이러스(RSV) 치료제 시장 성장 기회
  • 투여 형태별 : 세계의 호흡기세포융합바이러스(RSV) 치료제 시장 성장 기회
  • 환자 유형별 : 세계의 호흡기세포융합바이러스(RSV) 치료 시장 성장 기회
  • 지역별 : 세계의 호흡기세포융합바이러스(RSV) 치료 시장 성장 기회
• 세계의 호흡기세포융합바이러스(RSV) 치료제 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 호흡기세포융합바이러스(RSV) 치료제 시장 생산능력 확대
  • 세계 호흡기세포융합바이러스(RSV) 치료제 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증 및 라이선싱

제7장 주요 기업 개요

• Johnson & Johnson
• F. Hoffmann-La Roche
• Merck & Co.
• AbbVie
• Novartis
• Sanofi
• AstraZeneca
• Abbott Laboratories
• GlaxoSmithKline
• Gilead Sciences

영문목차

The future of the global respiratory syncytial virus (RSV) therapeutic market looks promising with opportunities in the palivizumab and ribavirin markets. The global respiratory syncytial virus (RSV) therapeutic market is expected to reach an estimated $3.4 billion by 2031 with a CAGR of 13.2% from 2025 to 2031. The major drivers for this market are the increase in the frequency of respiratory syncytial virus infection and the increasing disease rate.

• Lucintel forecasts that, within the treatment category, immune prophylaxis is expected to witness the highest growth over the forecast period.
• Within the drug category, palivizumab is expected to witness the highest growth.
• In terms of regions, North America is expected to witness the highest growth over the forecast period.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Respiratory Syncytial Virus (RSV) Therapeutic Market

There are emerging trends in the respiratory syncytial virus (RSV) therapeutic market that are changing the market as they are propelled by new developments in treatment, prevention, and awareness.

• Advancement in Monoclonal Antibodies: New monoclonal antibody treatment modalities are emerging, which are expected to assist in reducing RSV-related hospital visits, mostly among high-risk groups like children and the elderly. These therapies are becoming more popular because they effectively protect against the RSV virus.
• Vaccine Development Initiatives: There is a heightened need for the development of vaccines, with many vaccine candidates currently in clinical phases. A focus on pregnant women and infants is being leveraged to develop vaccination strategies that aim to provide more robust immunity in the early months of life when the risk of infection is high.
• Integration of Telemedicine: Telemedicine is helping to identify and treat RSV in the early stages, as symptoms can be tracked remotely, even in areas with poorly facilitated medical care.
• Increased Public Awareness Campaigns: More effective public health campaigns have resulted in greater awareness of what RSV is, what causes it, and other relevant information regarding its prevention. Training caregivers to recognize and manage RSV is critical to improving the timing of treatment.
• Integration Involving Pharmaceutical Corporations and Academic Institutions: Recent trends illustrate how pharmaceutical institutions, academia, and government organizations are forging partnerships, which speed up the development of new therapies and vaccines, further enhancing the response to RSV.

These trends are transforming the current treatment of patients with RSV by improving and expanding treatment options, enhancing prevention, and fostering collaboration among key players in the market, thus improving the condition of patients affected by this virus.

Recent Developments in the Respiratory Syncytial Virus (RSV) Therapeutic Market

The respiratory syncytial virus (RSV) therapeutic market has undergone several important changes that improve the control and management of the infectious disease.

• Effective Therapeutic Methods: Monoclonal Antibodies: Clinical trials and recent approvals of monoclonal antibody therapy demonstrate promising results, with a potential reduction in infant RSV hospitalizations. These treatments accommodate high-risk populations.
• Vaccines Being Developed: Several vaccine candidates that could offer protection against RSV for either infants or pregnant women are currently in clinical trials. These findings are important for preventing the worst forms of the disease.
• Improved Diagnostic Tools: Emerging diagnostic technologies have improved the timeliness and accuracy of RSV detection, aiding in the quick management of infections and reducing complications associated with delayed attention.
• Growing Attention Towards the Care of the Young: Healthcare systems are currently addressing pediatric RSV care and developing new practices and management strategies for babies and younger children, who are the most susceptible to the virus.
• United Research Partnerships: These partnerships ensure that viable RSV treatment alternatives and vaccine development processes are accelerated by the participation of stakeholders.

Such changes indicate a transition within the RSV therapeutic landscape, which is now more responsive to the demand for treatment, prevention, and improved clinical outcomes through better methods.

Strategic Growth Opportunities for Respiratory Syncytial Virus (RSV) Therapeutic Market

Although the market is dominated by the resurgence of RSV therapeutic tools, there are strategic opportunities for growth in several areas.

• Further Development of Vaccines: The possibilities in vaccine research and development are crucial for all population groups, including the very young, to prevent RSV infections. Effective immunizations are commercially viable options that help reduce the disease burden and related treatment costs.
• New Antiviral Medicines: Focusing on innovative antiviral medications can fill the gap left by existing treatments in the RSV category. The introduction of efficient antivirals will benefit many, particularly by enhancing the recovery of patients with severe RSV symptoms.
• Growth in Pediatric Healthcare: As RSV treatment is a growing concern, there is an opportunity to improve pediatric care facilities, such as specialized centers and management plans that focus on infants and toddlers.
• Advancements in Diagnostics: The acquisition and incorporation of modern diagnostic tools will facilitate the early detection of RSV in patients, enabling earlier treatment and better outcomes.
• Education and Awareness Programs: Developing targeted messages and awareness campaigns will help caregivers and healthcare providers in identifying and managing RSV, thereby facilitating its early management and hospitalization.

These growth opportunities are significant for improving the respiratory syncytial virus (RSV) therapeutic market and enhancing preventive and treatment measures, ultimately improving patient outcomes.

Respiratory Syncytial Virus (RSV) Therapeutic Market Driver and Challenges

The RSV therapeutic is quite complex because it faces many factors that either foster its development and growth or challenge it.

The factors responsible for driving the respiratory syncytial virus (RSV) therapeutic market include:

• Increased Awareness of RSV: This is owing to the increasing attention given by both healthcare professionals as well as the society concerning RS virus and its implications for high-risk groups. Therefore, demand for effective therapy and prevention approaches is on the rise.
• Advancements in Medical Research: Advancement in medical research is always inaction and more options for treatment such as monoclonal antibodies and vaccines are in prospect for RSV management.
• Government Support and Funding: There has been a substantial increase in government support and funding for programs focused on RSV disease and effective public health approaches helping to promote the development of adequate treatment and vaccination.
• Rising Incidence of RSV: The high incidence of RSV in infants and elderly populations particularly creates a critical need for the development of effective treatment and prevention approaches against the health dangers entailed.
• Global Collaboration in Healthcare: The innovative and collaborative approaches among stakeholders such as health practitioners, industry and other stakeholders have been speeding up the development of different strategists for RSV disease.

Challenges in the respiratory syncytial virus (RSV) therapeutic market are:

• Regulatory Hurdles: Assembling the necessary clinical evidence and navigating bureaucratic regulatory processes for the approval of new treatments and vaccines is a major challenge for developers, which can affect the timing of market entry.
• Cost of Research and Development: The high costs involved in the research and development (R&D) of new therapeutic medicines for RSV can be prohibitively expensive, particularly for smaller firms, which limits the market for innovative solutions.
• Public Perception and Awareness: While awareness of RSV has increased, there are still misconceptions about the disease that affect prevention and treatment strategies. There is a continued need for effective educational efforts.

The effective market drivers and constraints play a significant role in the RSV therapeutic market, affecting the development of new drugs. Addressing these challenges is the primary goal of all stakeholders who aim to improve patient health and bring RSV management to a new level.

List of Respiratory Syncytial Virus (RSV) Therapeutic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies respiratory syncytial virus (RSV) therapeutic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the respiratory syncytial virus (RSV) therapeutic companies profiled in this report include-

• Johnson & Johnson
• F. Hoffmann-La Roche
• Merck & Co.
• AbbVie
• Novartis
• Sanofi
• AstraZeneca
• Abbott Laboratories
• GlaxoSmithKline
• Gilead Sciences

Respiratory Syncytial Virus (RSV) Therapeutic by Segment

The study includes a forecast for the global respiratory syncytial virus (RSV) therapeutic market by drug, treatment, dosage form, patient type, and region.

Respiratory Syncytial Virus (RSV) Therapeutic Market by Drug [Analysis by Value from 2019 to 2031]:

• Palivizumab
• Ribavirin
• Others

Respiratory Syncytial Virus (RSV) Therapeutic Market by Treatment [Analysis by Value from 2019 to 2031]:

• Immune Prophylaxis
• Supportive Care
• Antiviral Medications

Respiratory Syncytial Virus (RSV) Therapeutic Market by Dosage Form [Analysis by Value from 2019 to 2031]:

• Oral
• Injectable
• Other

Respiratory Syncytial Virus (RSV) Therapeutic Market by Patient Type [Analysis by Value from 2019 to 2031]:

• Pediatrics
• Adults

Respiratory Syncytial Virus (RSV) Therapeutic Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Respiratory Syncytial Virus (RSV) Therapeutic Market

Recent developments in the respiratory syncytial virus (RSV) therapeutic market have been driven by increased knowledge and efforts to address therapeutic gaps, particularly among vulnerable populations such as children and the elderly. Countries like the United States, China, Germany, India, and Japan are actively engaging in research and development to provide solutions for the RSV threat. These developments include new, more effective therapies, advances in diagnostics, and improved prophylactic measures, all of which help reduce the burden of the virus and change the outlook for RSV management in the coming years.

• United States: In the United States, several novel RSV treatments are either in clinical trials or already available. Recently, the FDA granted breakthrough therapy designation to monoclonal antibodies targeting RSV, aimed at high-risk patients, demonstrating the need for effective alternatives. Additionally, public health initiatives are working to increase the use of vaccination in babies. The growing attention to antiviral drugs and combination therapies in RSV research and development is also encouraging. Furthermore, the approach to RSV treatment is shifting from disease management to prevention and treatment.
• China: China is making significant progress in developing the RSV therapeutic sector, supported by increased research investment and foreign pharmaceutical firms operating in the country. Some local biotech companies are now involved in developing RSV vaccines and antiviral drugs, driven by the need for improved nursing care for RSV-infected children. Moreover, changes are being made in raising awareness about RSV prevention and treatment among the population. The use of traditional Chinese medicine in combination with standard medicine is also being investigated to improve outcomes. These efforts indicate a growing commitment to improving care for RSV-infected children.
• Germany: In Germany, several clinical trials are exploring new and innovative therapeutic approaches for RSV, such as monoclonal antibodies and antivirals. Key health authorities in Germany are overseeing research focused on high-risk populations, including premature infants and the elderly. Additionally, considerable attention is being given to vaccine development. Educational resources are being utilized in collaboration with healthcare institutions to increase understanding and improve screening for RSV. The use of new-generation technologies is expected to enhance diagnosis and treatment, minimizing hospital stays for RSV patients.
• India: The RSV market in India is maturing, with increasing R&D activity. In recent years, government agencies and private companies have focused on developing effective prophylactic and therapeutic approaches. More healthcare practitioners are recognizing the significance of RSV, leading to better management of the disease. Additionally, community health initiatives will play a key role in educating caregivers about how RSV can be prevented. These initiatives are particularly important in minimizing the RSV disease burden on young children, especially in areas with limited healthcare infrastructure.
• Japan: Japan is making steady progress in the RSV market, with ongoing vaccine development and new antiviral treatment options emerging. Japanese pharmaceutical companies have been conducting more clinical studies of modern monoclonal antibodies and promising vaccine candidates. The government supports these initiatives through funding and favorable legal conditions, recognizing the need for effective RSV management. Furthermore, healthcare providers are considering early treatment with antibiotics for children diagnosed at risk for RSV. Public health programs are also being implemented to reduce RSV infection rates by educating caregivers about prevention.

Features of the Global Respiratory Syncytial Virus (RSV) Therapeutic Market

Market Size Estimates: Respiratory syncytial virus (RSV) therapeutic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by various segments and regions.

Segmentation Analysis: Respiratory syncytial virus (RSV) therapeutic market size by various segments, such as by drug, treatment, dosage form, patient type, and region in terms of value ($B).

Regional Analysis: Respiratory syncytial virus (RSV) therapeutic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drugs, treatments, dosage forms, patient types, and regions for the respiratory syncytial virus (RSV) therapeutic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the respiratory syncytial virus (RSV) therapeutic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the respiratory syncytial virus (RSV) therapeutic market by drug (palivizumab, ribavirin, and others), treatment (immune prophylaxis, supportive care, and antiviral medications), dosage form (oral, injectable, and other), patient type (pediatrics and adults), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Respiratory Syncytial Virus (RSV) Therapeutic Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Respiratory Syncytial Virus (RSV) Therapeutic Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Drug
  • 3.3.1: Palivizumab
  • 3.3.2: Ribavirin
  • 3.3.3: Others
• 3.4: Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Treatment
  • 3.4.1: Immune Prophylaxis
  • 3.4.2: Supportive Care
  • 3.4.3: Antiviral Medications
• 3.5: Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Dosage Form
  • 3.5.1: Oral
  • 3.5.2: Injectable
  • 3.5.3: Other
• 3.6: Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Patient Type
  • 3.6.1: Pediatrics
  • 3.6.2: Adults

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Region
• 4.2: North American Respiratory Syncytial Virus (RSV) Therapeutic Market
  • 4.2.1: North American Market by Drug: Palivizumab, Ribavirin, and Others
  • 4.2.2: North American Market by Treatment: Immune Prophylaxis, Supportive Care, and Antiviral Medications
• 4.3: European Respiratory Syncytial Virus (RSV) Therapeutic Market
  • 4.3.1: European Market by Drug: Palivizumab, Ribavirin, and Others
  • 4.3.2: European Market by Treatment: Immune Prophylaxis, Supportive Care, and Antiviral Medications
• 4.4: APAC Respiratory Syncytial Virus (RSV) Therapeutic Market
  • 4.4.1: APAC Market by Drug: Palivizumab, Ribavirin, and Others
  • 4.4.2: APAC Market by Treatment: Immune Prophylaxis, Supportive Care, and Antiviral Medications
• 4.5: ROW Respiratory Syncytial Virus (RSV) Therapeutic Market
  • 4.5.1: ROW Market by Drug: Palivizumab, Ribavirin, and Others
  • 4.5.2: ROW Market by Treatment: Immune Prophylaxis, Supportive Care, and Antiviral Medications

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Drug
  • 6.1.2: Growth Opportunities for the Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Treatment
  • 6.1.3: Growth Opportunities for the Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Dosage Form
  • 6.1.4: Growth Opportunities for the Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Patient Type
  • 6.1.5: Growth Opportunities for the Global Respiratory Syncytial Virus (RSV) Therapeutic Market by Region
• 6.2: Emerging Trends in the Global Respiratory Syncytial Virus (RSV) Therapeutic Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Respiratory Syncytial Virus (RSV) Therapeutic Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Respiratory Syncytial Virus (RSV) Therapeutic Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Johnson & Johnson
• 7.2: F. Hoffmann-La Roche
• 7.3: Merck & Co.
• 7.4: AbbVie
• 7.5: Novartis
• 7.6: Sanofi
• 7.7: AstraZeneca
• 7.8: Abbott Laboratories
• 7.9: GlaxoSmithKline
• 7.10: Gilead Sciences